Here's Why Altria (MO) is a Strong Growth Stock

Altria (MO) is highlighted by Zacks as a potential growth opportunity, driven by its successful transition from traditional cigarettes to the expanding smokeless product category. Despite a Zacks Rank #3 (Hold), MO holds a B-rated Growth Style Score and VGM Score, underpinned by a forecasted 4.9% earnings growth for the current fiscal year and recent analyst upgrades to its fiscal 2025 earnings estimate to $5.37 per share, suggesting continued earnings expansion amidst evolving industry dynamics.

Analysis

Altria Group (MO) is presented as a company effectively navigating a structural industry transition away from traditional cigarettes. Its strategic pivot towards the smokeless and reduced-risk product categories is yielding tangible results, evidenced by steadily rising revenues from its oral products division. While the stock currently holds a neutral Zacks #3 (Hold) rank, its underlying growth indicators are positive. It secures a 'B' grade for its Growth Style Score and its overall VGM Score, underpinned by a forecasted 4.9% year-over-year earnings growth for the current fiscal year. Furthermore, forward-looking sentiment from analysts appears to be improving, with two upward revisions to fiscal 2025 earnings estimates in the last 60 days, lifting the consensus target by $0.02 to $5.37 per share. The company's operational consistency is also highlighted by its average positive earnings surprise of 1.3%, suggesting a stable execution of its strategy.

Key Decisions for Investors

• Growth-oriented investors should consider Altria's strategic pivot to smokeless products and its projected 4.9% earnings growth, which position it as a potential value-growth opportunity despite its mature industry.
• It is prudent to monitor for further upward earnings estimate revisions, as continued positive momentum could serve as a catalyst for a potential upgrade from its current Zacks #3 (Hold) rating.
• Investors should weigh the growth prospects in the expanding oral products category against the persistent regulatory and health-related headwinds facing the legacy tobacco business.